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Abstract: Peptide drug discovery may play a key role in the identification of novel medicinal agents.
Here, we present the development of novel small peptides able to suppress the production of PGE2
in mesangial cells. The new compounds were generated by structural alterations applied on GK115,
a novel inhibitor of secreted phospholipase A2, which has been previously shown to reduce PGE2
synthesis in rat renal mesangial cells. Among the synthesized compounds, the tripeptide derivative 11
exhibited a nice dose-dependent suppression of PGE2 production, similar to that observed for GK115.
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1. Introduction
Prostaglandin E2 (PGE2) is one of the most important lipid mediators [1] playing a pivotal role
in inflammatory diseases [2] including glomerulonephritis. Glomerulonephritis is initiated by the
invasion of activated immune cells into the renal glomerulus and the release of pro-inflammatory
cytokines such as TNFα and interleukin (IL) 1β to activate the local resident mesangial cells [3,4].
This activation includes three main responses, i.e., increased proliferation, increased matrix production,
and increased inflammatory mediator production, which are all hallmarks of glomerulonephritis,
finally resulting in glomerulosclerosis and renal failure [4]. Due to this central involvement of mesangial
cells in the pathogenesis of chronic inflammatory kidney diseases, they serve as a useful cellular model
system to test for new therapeutic compounds to treat such diseases.
The biosynthesis of PGE2 is initiated by the action of phospholipases A2 (PLA2), which cleave the
sn-2 ester bond of membrane glycerophospholipids to release arachidonic acid [5,6]. Then, arachidonic
acid is converted to PGH2 and the terminal step of PGE2 generation is catalyzed by microsomal
prostaglandin synthase-1 [7]. Four types of PLA2 [6] are expressed at mesangial cells: cytosolic (cPLA2)
GIVA, calcium-independent (iPLA2) GVIA and secreted (sPLA2) GIIA and GV [8–10]. It has been
demonstrated that the progression of glomerular inflammatory processes is a result of a network
of interactions between different PLA2s [9] and a cross-talk between cPLA2 and sPLA2 has been
reported in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells [11].
In addition, sPLA2 GIIA seems to have multiple roles in mesangial cells inducing the production of
pro-inflammatory mediators [12].
We have recently demonstrated that inhibitors of sPLA2 suppress the release of PGE2 formation
in renal mesangial cells [13]. Four such inhibitors presented an interesting effect on the suppression of
PGE2 release and their structures are shown in Figure 1. Inhibitors 1 (GK115) [14] and 2 [15] are amides
based on the non-natural amino acids γ-norleucine and γ-tyrosine, respectively, while inhibitors 3
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(GK126) [16] and 4 (GK241) [17] are 2-oxoamides based on the natural amino acids leucine and valine,
respectively. As depicted in Figure 1, all of them are characterized by high lipophilicity (ClogP value
higher than 5), an unfavorable property according to Lipinski’s rule of 5 [18]. The ClogP values of the
inhibitors were calculated using ChemOffice Ultra 11.00.
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2. Results 
2.1. Synthesis 
Inspired by the structure of inhibitor GK115 and considering it as a lead compound, we designed 
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of GK115 (Group A, Figure 2) by a chain based on the benzoyl derivative of the peptide glycyl-glycine
(Group C, Figure 2).
Compound 7 was synthesized by coupling of 7-phenyl-heptanoic acid 5 with the dipeptide
norleucyl-glycine using 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (WSCI) as a condensing
agent in the presence of 1-hydroxybenzotriazole (HOBt), followed by alkaline hydrolysis (Scheme 1).
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2.2. Suppression of PGE2 Release in Mesangial Cells
Cultures of rat renal mesangial cells were stimulated for 24 h with IL-1β plus forskolin (Fk) to
trigger a huge increase of PGE2 synthesis, as previously described [20]. Cells were treated in the
absence or presence of three different concentrations (1 µM, 3 µM and 10 µM) of the various synthetic
compounds. Supernatants were collected and subjected to PGE2-ELISA to quantify PGE2 released
from the cells.
The results of the suppression of PGE2 release in mesangial cells caused by the new peptides
derivatives are shown in Figure 3. In the absence of IL-1β plus Fk, none of the compounds, tested at
the highest concentration of 10 µM, changed the basal PGE2 synthesis significantly (data not shown).
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be noticed that this derivative seems efficiently protected by he action of oth aminopeptidases
and carboxypeptid ses. Peptides based on γ-amino acids are resistant t carboxypeptidases [21],
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with ClogP val es of 1.51, 1.51 and 0.94, respectively. These results confirm our hypothesis that we
could i prove compounds’ lipophilicity, while preserve their potency to suppress PGE2 release.
2.3. Docking Studies
Since we have shown that inhibition of sPLA2 is a possible path via which our sPLA2 inhibitors
(GK115, GK126 and GK241) evoke the suppression of PGE2 release [13], we performed docking
calculations for the binding pose prediction of c mpounds GK115 and 11 in the active site of
the enzyme.
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Sybyl 8.0 [22] by TRIPOS was used for the design and the energy minimization of the structures.
The carboxyl group was considered deprotonated and the Powell algorithm was used for the energy
minimization. The crystal structure of sPLA2 GIIA was retrieved from the Brookhaven Protein
Databank (code: 1KQU) and used for the docking calculations. The protein’s missing loops were
added with the Prime module of Schrödinger Suite [23]. The molecules were placed in the active site
of the enzyme manually in Chimera [24] and docked in AutoDock Vina [25].
By visual inspection of the docking results, docking poses which reproduced the known
interactions between the co-crystallized ligands and the enzyme, were chosen and subjected to
molecular dynamics (MD) simulations with AMBER14 [26], following a standard procedure [17].
MD simulations (100 ns) were run and the top cluster of each simulation is shown in Figures 4 and 5.
For the clustering, the hieragglo algorithm was used and the averagelinkage option in cpptraj [27] was
defined using the Leu2, Phe5, His6, Ile9, Ala17-Gly32, Cys44, His47, Asp48, Lys62, Asp91 and Phe98
amino acids.
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The carboxyl group of both molecules and the carbonyl group of the Nle-Gly peptide bond of
11 and the amide group of GK115 chelate the Ca2+ ion throughout the simulation time. Additionally,
a hydrogen bond is formed between His47 and the -NH group of the peptide bond of 11 and the amide
group of GK115, respectively. These interactions are present in the crystallized structures of sPLA2
GIIA with the native ligands [15]. Both inhibitors adopt similar conformation in the active site and
they preserve it, with small fluctuations, during the MD time (Figure 6).
This further contributes to the persistence of the interactions between the molecules and the
residues of the active site. MM-PBSA [28] method was used for the estimation of the energetic terms of
both systems. The ∆H value for inhibitor GK115 is −47.16 kcal/mol with a standard deviation error
(SDE) 5.16 kcal/mol and for compound 11 is −38.22 kcal/mol with SDE of 6.26 kcal/mol. Since GK115
Molecules 2018, 23, 158 6 of 10
is a potent inhibitor of sPLA2 GIIA, both the key interactions and the ∆H values calculated by the MD
trajectories are a good indicator of a possible inhibition of sPLA2 GIIA by 11 and biological assays will
be performed in a future study to investigate this possibility.
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3. Discussion
Our studies led to the identification of a number of small peptides derivatives that present
a significant suppression of PGE2 release in renal mesangial cells. Among them, benzoyl-glycyl-
glycyl-γ-(R)-norleucine (11) showed an interesting effect on the suppression of PGE2 formation. This
tripeptide derivative has a significant lower lipophilicity in comparison to the lead compound GK115
without loss of the ability to suppress PGE2 release at a cellular level. Thus, new agents that can serve
as leads to reduce pathological PGE2 production, as seen in chronic inflammatory kidney diseases
such as glomerulonephritis, have been identified.
4. Materials and Methods
4.1. Chemistry
Merck Silica Gel 60 (70–230 or 230–400 mesh) (Merck Co., Darmstadt, Germany) was used for the
chromatographic purification of products and Silica Gel 60 F254 (Merck Co., Darmstadt, Germany)
aluminum plates for the thin-layer chromatography (TLC). UV light and/or phosphomolybdic acid in
EtOH was employed for visualizing shpots. A Büchi 530 apparatus (Buchi, Flawil, Switzerland) was
used to estimate melting points and they were uncorrected. 1H and 13C–NMR spectra were recorded on
Varian Mercury (Varian Inc., Palo Alto, CA, USA) at 200 MHz and 50 MHz respectively. Samples were
diluted in CDCl3, CD3OD, DMSO or D2O. Chemical shifts are given in ppm, and coupling constants
(J) in Hz. Peak multiplicities are typified as: s, singlet, d, doublet, t, triplet and m, multiplet. Electron
spray ionization (ESI) mass spectra were recorded on a Finnigan, Surveyor MSQ Plus spectrometer
(Thermo Finnigan, Ringoes, NJ, USA). Specific rotations of the compounds were measured at 25 ◦C on a
Perkin-Elmer 343 polarimeter (PerkinElmer Inc., Shelton, CT, USA) using a 10 cm cell. Dichloromethane
was dried by standard procedures and stored over molecular sieves. No further purification of other
solvents and chemicals needed as they were reagent grade. HRMS spectra were recorded on a Bruker
Maxis Impact QTOF Spectrometer (Bruker Daltonics, Billerica, MA, USA).
4.1.1. Coupling Method
To a stirred solution of hydrochloride amino component (1.0 mmol) in CH2Cl2 (10 mL), Et3N
(0.3 mL, 2.2 mmol) and subsequently WSCI·HCl (0.21 g, 1.1 mmol) and HOBt (0.14 g, 1.0 mmol) were
added at 0 ◦C. The acid component (1.0 mmol) was added and the reaction mixture was stirred for
1 h at 0 ◦C and then overnight at room temperature. After the completion of the reaction, the solvent
was evaporated under reduced pressure and EtOAc (20 mL) was added. The organic layer was
washed consecutively with brine, 1 N aqueous HCl, brine, 5% NaHCO3, and brine, dried over Na2SO4
and evaporated under reduced pressure. The residue was purified by column chromatography
[EtOAc/petroleum ether (bp 40–60 ◦C), 2:8].
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(R)-Methyl 2-(2-(7-phenylheptanamido)hexanamido)acetate (6). Yield 77%; Colorless oil; [α]20D + 33.0
(c 1.00, CH3OH); 1H–NMR (CDCl3, 200 MHz): δ 7.72 (t, J = 5.5 Hz, 1H, NH), 7.33–7.07 (m, 5H, arom),
6.91 (d, J = 8.3 Hz, 1H, NH), 4.63 (dt, J = 7.5 Hz, 1H, NHCH), 4.19–3.81 (m, 2H, NHCH2), 3.68 (s, 3H,
COOCH3), 2.57 (t, J = 7.6 Hz, 2H, CH2), 2.19 (t, J = 7.4 Hz, 2H, NHCOCH2), 1.92–1.45 (m, 6H, CH2),
1.44–1.16 (m, 8H, CH2), 0.87 (t, J = 6.7 Hz, 3H, CH3); 13C–NMR (CDCl3, 50 MHz): δ 173.3, 172.8, 169.8,
142.4, 128.5, 128.0, 125.4, 52.6, 52.0, 40.9, 36.1, 35.7, 32.2, 31.6, 28.9, 28.8, 27.4, 25.4, 22.3, 13.8; MS (ESI)
m/z (%): 391.14 (92) [M + H]+; Anal. Calcd for C22H34N2O4: C, 67.66; H, 8.78; N, 7.17. Found: C, 67.49;
H, 8.97; N, 7.03.
(R)-Methyl 4-(2-(2-benzamidoacetamido)acetamido)octanoate (10). Yield 62%; Yellow oil; [α]20D + 1.5
(c 1.00, CHCl3); 1H–NMR (CDCl3, 200 MHz): δ 8.19–8.02 (m, 1H, NH), 7.87–7.67 (m, 3H, NH & arom),
7.51–7.24 (m, 3H, NH & arom), 7.03–6.86 (m, 1H, arom), 4.03 (d, J = 4.5 Hz, 2H, NHCH2), 3.85 (d,
J = 5.0 Hz, 2H, NHCH2), 3.75–3.69 (m, 1H, NHCH), 3.53 (s, 3H, COOCH3), 2.26 (t, J = 7.3 Hz, 2H,
CH2COO), 1.92–1.52 (m, 2H, NHCHCH2), 1.48–1.03 (m, 6H, CH2), 0.87–0.65 (m, 3H, CH3); 13C–NMR
(CDCl3, 50 MHz): δ 174.1, 170.1, 168.8, 168.3, 132.9, 131.8, 128.4, 127.2, 51.5, 49.0, 43.9, 43.0, 34.5, 30.5,
29.7, 27.9, 22.4, 13.8; MS (ESI) m/z (%): 392.14 (90) [M + H]+; Anal. Calcd for C20H29N3O5: C, 61.36; H,
7.47; N, 10.73. Found: C, 61.15; H, 7.74; N, 10.54.
(R)-Methyl 2-(2-(2-benzamidoacetamido)acetamido)hexanoate (13a). Yield 53%; White solid; mp
140–142 ◦C; [α]20D + 18.6 (c 1.02, CHCl3); 1H–NMR (CDCl3, 200 MHz): δ 7.95–7.66 (m, 4H, NH & arom),
7.52–7.27 (m, 4H, arom), 4.45 (dt, J = 7.5 Hz, 1H, NHCH), 4.10 (d, J = 5.1 Hz, 2H, NHCH2), 4.06–3.82
(m, 2H, NHCH2), 3.63 (s, 3H, COOCH3), 1.86–1.49 (m, 2H, NHCHCH2), 1.34–1.09 (m, 4H, CH2), 0.80
(t, J = 6.6 Hz, 3H, CH3); 13C–NMR (CDCl3, 50 MHz): δ 173.0, 170.2, 169.2, 168.1, 133.2, 131.7, 128.4,
127.2, 52.4, 52.2, 43.7, 42.8, 31.4, 27.4, 22.1, 13.7; MS (ESI) m/z (%): 364.09 (90) [M + H]+; Anal. Calcd for
C18H25N3O5: C, 59.49; H, 6.93; N, 11.56. Found: C, 59.40; H, 7.03; N, 11.47.
(S)-Methyl 2-(2-(2-benzamidoacetamido)acetamido)hexanoate (13b). Yield 68%; White solid; mp
139–141 ◦C; [α]20D − 18.0 (c 1.00, CHCl3); 1H–NMR (CDCl3, 200 MHz): δ 8.04 (t, J = 4.9 Hz, 1H,
NH), 7.88 (t, J = 5.1 Hz, 1H, NH), 7.83–7.69 (m, 2H, NH & arom), 7.62–7.46 (m, 1H, arom), 7.45–7.19 (m,
3H, arom), 4.40 (dt, J = 7.6 Hz, 1H, NHCH), 4.06 (d, J = 4.7 Hz, 2H, NHCH2), 4.00–3.80 (m, 2H, NHCH2),
3.59 (s, 3H, COOCH3), 1.86–1.47 (m, 2H, NHCHCH2), 1.32–1.05 (m, 4H, CH2), 0.77 (t, J = 6.7 Hz, 3H,
CH3); 13C–NMR (CDCl3, 50 MHz): δ 173.0, 170.2, 169.2, 168.1, 133.1, 131.6, 128.2, 127.2, 52.3, 52.0,
43.6, 42.7, 31.3, 27.4, 22.0, 13.6; MS (ESI) m/z (%): 364.04 (90) [M + H]+; Anal. Calcd for C18H25N3O5:
C, 59.49; H, 6.93; N, 11.56. Found: C, 59.20; H, 7.15; N, 11.35.
(R)-tert-Butyl 9-butyl-1,4,7,10-tetraoxo-1-phenyl-2,5,8,11-tetraazatridecan-13-oate (15a). Yield 92%;
White solid; mp 177–178 ◦C; [α]20D + 11.0 (c 1.00, CH3OH); 1H–NMR (CDCl3, 200 MHz): δ 8.25–8.07 (m,
1H, NH), 8.05–7.94 (m, 1H, NH), 7.93–7.76 (m, 3H, NH & arom), 7.75–7.58 (m, 1H, arom), 7.55–7.29 (m,
3H, arom), 4.96–4.74 (m, 1H, NHCH), 4.43–4.25 (m, 2H, NHCH2), 4.22–4.03 (m, 2H, NHCH2), 4.01–3.71
(m, 2H, NHCH2), 1.94–1.49 (m, 2H, CH2), 1.40 (s, 9H, CH3), 1.33–1.10 (m, 4H, CH2), 0.81 (t, J = 6.7 Hz,
3H, CH3); 13C–NMR (CDCl3, 50 MHz): δ 172.2, 169.6, 168.7, 168.5, 167.9, 133.5, 131.6, 128.3, 127.4, 81.9,
53.0, 43.5, 41.9, 33.1, 27.9, 27.5, 25.9, 22.4, 13.9; MS (ESI) m/z (%): 463.22 (90) [M + H]+; Anal. Calcd for
C23H34N4O6: C, 59.72; H, 7.41; N, 12.11. Found: C, 59.44; H, 7.70; N, 11.93.
4.1.2. Saponification of Methyl Esters
To a stirred solution of a methyl ester (1.0 mmol) in water, 1 N aqueous NaOH (1 mL, 1.0 mmol)
was added and the mixture was left under stirring overnight at room temperature. After the completion
of the reaction, the mixture was washed with EtOAc (3 × 10 mL), acidified with 1 N aqueous HCl to
pH 1 and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine,
dried over Na2SO4 and evaporated under reduced pressure.
(R)-2-(2-(7-Phenylheptanamido)hexanamido)acetic acid (7). Yield 83%; White oil; [α]20D + 15.0 (c 1.00,
CH3OH); 1H–NMR (CDCl3, 200 MHz): δ 9.67 (br s, 1H, COOH), 7.72–7.45 (m, 2H, NH), 7.36–6.99 (m,
5H, arom), 4.76–4.51 (m, 1H, NHCH), 4.13–3.86 (br s, 2H, NHCH2), 2.69–2.39 (m, 2H, CH2), 2.31–2.05
(m, 2H, NHCOCH2), 1.92–1.45 (m, 6H, CH2), 1.41–1.05 (m, 8H, CH2), 0.96–0.69 (m, 3H, CH3); 13C–NMR
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(CDCl3, 50 MHz): δ 174.3, 172.9, 172.0, 142.5, 128.2, 128.1, 125.5, 52.8, 41.2, 36.1, 35.7, 32.1, 31.2, 28.9,
28.9, 27.4, 25.5, 22.2, 13.8; HRMS (ESI) calcd for C21H33N2O4 [M + H]+: 377.2435. Found: 377.2438;
Anal. Calcd for C21H32N2O4: C, 66.99; H, 8.57; N, 7.44. Found: C, 66.72; H, 8.86; N, 7.27.
(R)-4-(2-(2-Benzamidoacetamido)acetamido)octanoic acid (11). Yield 88%; White solid; mp 202–204 ◦C;
[α]20D + 4.0 (c 1.00, CH3OH);
1H–NMR (D2O, 200 MHz): δ 7.89–7.70 (m, 2H, arom), 7.68–7.41 (m, 3H,
arom), 4.07 (s, 2H, NHCH2), 3.88 (s, 2H, NHCH2), 3.82–3.64 (m, 1H, NHCH), 2.10 (t, J = 6.7 Hz, 2H,
CH2COOH), 1.93–1.06 (m, 8H, CH2), 0.89–0.66 (m, 3H, CH3); 13C–NMR (D2O, 50 MHz): δ 182.9,
172.4, 171.4, 170.9, 132.7, 132.5, 128.9, 127.4, 50.0, 34.2, 33.6, 31.2, 27.5, 21.9, 13.4; HRMS (ESI) calcd for
C19H28N3O5 [M + H]+: 378.2023. Found: 378.2025; Anal. Calcd for C19H27N3O5: C, 60.46; H, 7.21;
N, 11.13. Found: C, 60.25; H, 7.42; N, 11.01.
(R)-2-(2-(2-Benzamidoacetamido)acetamido)hexanoic acid (14a). Yield 93%; White solid; mp 213–215 ◦C;
[α]20D + 8.6 (c 1.00, CH3OH);
1H–NMR (DMSO, 200 MHz): δ 8.84 (t, J = 5.6 Hz, 1H, NH), 8.19 (t, J = 5.5 Hz,
1H, NH), 8.05–7.70 (m, 3H, NH & arom), 7.58–7.24 (m, 3H, arom), 4.22–4.02 (m, 1H, NHCH), 3.85 (d,
J = 5.6 Hz, 2H, NHCH2), 3.72 (d, J = 5.6 Hz, 2H, NHCH2), 1.76–1.43 (m, 2H, CH2), 1.35–1.01 (m, 4H,
CH2), 0.79 (t, J = 6.5 Hz, 3H, CH3); 13C–NMR (DMSO, 50 MHz): δ 173.6, 169.3, 168.8, 166.7, 133.9, 131.5,
128.3, 127.4, 51.8, 42.9, 41.8 30.8, 27.5, 21.8, 13.8; HRMS (ESI) calcd for C17H24N3O5 [M + H]+: 350.1710.
Found: 350.1711; Anal. Calcd for C17H23N3O5: C, 58.44; H, 6.64; N, 12.03. Found: C, 58.22; H, 6.86;
N, 11.87.
(S)-2-(2-(2-Benzamidoacetamido)acetamido)hexanoic acid (14b). Yield 91%; White solid; mp 192–201 ◦C;
[α]20D − 8.1 (c 1.08, CH3OH); 1H–NMR (CDCl3 and drops CD3OD, 200 MHz): δ 7.82–7.58 (m, 1H, arom),
7.53–7.14 (m, 4H, arom), 4.38–4.21 (m, 1H, NHCH), 4.05 (s, 2H, NHCH2), 3.96 (s, 2H, NHCH2), 1.87–1.43
(m, 2H, CH2), 1.34–1.09 (m, 4H, CH2), 0.75 (t, J = 6.5 Hz, 3H, CH3); 13C–NMR (DMSO, 50 MHz): δ 173.8,
168.9, 169.0, 166.5, 134.3, 131.8, 128.7, 127.0, 51.4, 43.2, 41.1 31.2, 27.3, 21.2, 13.4; HRMS (ESI) calcd for
C17H24N3O5 [M + H]+: 350.1710. Found: 350.1712; Anal. Calcd for C17H23N3O5: C, 58.44; H, 6.64;
N, 12.03. Found: C, 58.24; H, 6.82; N, 11.90.
4.1.3. Cleavage of tert-Butyl Protecting Group
A solution of the tert-butyl ester derivative (1 mmol) in 50% TFA/CH2Cl2 (0.5 M) was stirred for
2 h at room temperature. After the completion of the reaction, the organic solvent was evaporated
under reduced pressure and the residue was purified by recrystallization.
(R)-9-Butyl-1,4,7,10-tetraoxo-1-phenyl-2,5,8,11-tetraazatridecan-13-oic acid (16a). Yield 87%; White
solid; mp 195–206 ◦C; [α]20D + 20.0 (c 1.00, CH3OH); 1H–NMR (CD3OD, 200 MHz): δ 7.91–7.77 (m, 2H,
arom), 7.59–7.35 (m, 3H, arom), 4.45–4.32 (m, 1H, NHCH), 4.26 (s, 2H, NHCH2), 4.05 (s, 2H, NHCH2),
3.90 (s, 2H, NHCH2), 1.97–1.57 (m, 2H, CH2), 1.41–1.16 (m, 4H, CH2), 0.86 (t, J = 6.6 Hz, 3H, CH3);
13C–NMR (CD3OD, 50 MHz): δ 173.2, 171.8, 171.2, 170.2, 169.2, 133.3, 132.2, 128.7, 127.5, 53.6, 43.7, 42.9,
31.6, 28.0, 22.4, 22.3, 13.9; HRMS (ESI) calcd for C19H27N4O6 [M + H]+: 407.1925. Found: 407.1927;
Anal. Calcd for C19H26N4O6: C, 56.15; H, 6.45; N, 13.79. Found: C, 55.84; H, 6.62; N, 13.65.
4.2. Biology
4.2.1. Cell Culture
The methods used for the isolation, characterization and cultivation of rat renal mesangial cells
have been previously described in details [29]. Confluent cells were incubated in 24-well-plates for 4 h
in serum-free DMEM including 0.1 mg/mL of fatty acid-free bovine serum albumin. Subsequently,
cells were preincubated for 20 min either with the vehicle or the indicated concentrations of the
various inhibitors prior to stimulation with IL1β (1 nM) plus Fk (5 µM) in the presence of the
inhibitors for 24 h. The total stimulation volume per well was 500 µL. Cell supernatants were taken for
PGE2 quantification.
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4.2.2. Quantification of Prostaglandin E2
A PGE2-specific enzyme-linked immunosorbent assay (ELISA) kit (from Enzo Life Science,
Lörrach, Germany) was used for the quantification of PGE2 in the cell culture supernatants. 100 µL of
the supernatants were processed according to the manufacturer’s instructions.
4.2.3. Statistical Analysis
Statistical analysis of data was performed using one-way ANOVA following Bonferroni post-hoc
test for multiple comparisons.
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